Kurt C. Wheeler is a Senior Managing Director in the Blackstone Life Sciences group, having joined Blackstone as part of its acquisition of Clarus in December of 2018. Prior to joining Blackstone, Mr. Wheeler was a co-founder and Managing Director of Clarus since the firm's inception in 2005.
Mr. Wheeler has over 30 years of direct investment and industry operating experience within the healthcare sector where he has led investments in the medical technology, specialty pharmaceutical and biotechnology space including partnerships with pharmaceutical companies. Prior to Clarus, Mr. Wheeler was a General Partner at MPM Capital, a healthcare venture capital firm. Mr. Wheeler was a co-founder and CEO of InControl (NASDAQ:INCL), a medical device company which he sold to Guidant. Prior to founding InControl he was a Principal with the Mayfield Fund focused on healthcare investing. Mr. Wheeler began his career with Elli Lilly Co. Currently Mr. Wheeler is a member of the Board of Directors of Avillion LLP, Globus Medical (NYSE: GMED) and Flowonix.
Mr. Wheeler holds a BA from Brigham Young University, and an MBA from Northwestern University's Kellogg School.